Heparanase in Cancer, Angiogenesis, and Kidney Disease

Heparanase is, to date, the only mammalian enzyme known to cleave heparan sulfate internally — an activity that sounds obscure until you realize how much of cell signaling, barrier function, and tumor spread depends on that one polysaccharide. If your search started with a question like "what does high heparanase mean," "heparanase inhibitor," or "heparanase and cancer," you are in good company: the enzyme sits at the crossroads of metastasis research, diabetic kidney disease, and a still-unapproved but actively pursued class of anti-cancer drugs. For labs working on these questions, we supply heparanase (HPSE) ELISA kits, heparanase activity-assay reagents built on a heparan sulfate substrate, and matched antibody pairs for heparan sulfate fragments, syndecan-1, and glypican, along with custom assay development when a study needs a particular readout.

What Heparanase Actually Does

Heparanase, encoded by the HPSE gene, is an endo-β-D-glucuronidase: it cuts within the heparan sulfate chains that decorate cell-surface and basement-membrane proteoglycans, rather than nibbling at their ends. The protein is made as a latent proenzyme and matured in lysosomes, where proteolysis of a short linker peptide yields the active ~50 kDa and ~8 kDa subunits that remain associated as a heterodimer. That heterodimer is what actually degrades heparan sulfate in the extracellular space. The enzyme works best at acidic pH inside lysosomes but is also active at near-neutral extracellular pH, which is why it can remodel the matrix outside the cell. Its substrate — heparan sulfate proteoglycans — is not just structural scaffolding. The negatively charged sugar chains bind and present a depot of bioactive molecules: vascular endothelial growth factor (VEGF), fibroblast growth factor-2, chemokines, and cytokines. When heparanase trims those chains, it loosens the extracellular matrix and releases that bound payload into the local environment.

Figure 1. Scheme of heparan sulfate and the heparanase cleavage site, and of perlecan, a basement membrane HSPG. (Source: Zcharia E, et al. 2001)

The Heparan Sulfate Ecosystem

To read a heparanase result you have to read it inside the heparan sulfate system. The proteoglycans come in families: syndecans are transmembrane and tether growth factors at the cell surface, glypicans are GPI-anchored, and perlecan sits in basement membranes. All three are heparanase substrates, and all three are why heparanase activity has consequences far beyond "cutting sugar." A cleaved syndecan-1 chain releases its attached growth factors and chemokines; a trimmed perlecan weakens the basement membrane that tumor cells must cross. Heparanase also collaborates with proteinases such as matrix metalloproteinases — the carbohydrate and protein arms of matrix remodeling reinforce each other — and it rides in extracellular vesicles, so a cell can hand heparanase activity to a neighbor without exporting the enzyme in free form. None of this is housekeeping; it is the mechanics of how a tissue becomes permissive to invasion.

Heparanase in Cancer

This is where most heparanase searches land. Over-expression of HPSE is common across carcinomas, sarcomas, and hematologic malignancies, and in study after study it tracks with microvessel density and poorer outcome. The mechanism is concrete rather than vague: by shedding heparan sulfate, the enzyme frees VEGF and other angiogenic factors, promoting new vessel formation; it weakens the endothelial and basement-membrane barriers that tumor cells must traverse to enter and leave the circulation; and it can act on endothelial cells directly. A 2021 investigation showed heparanase released from hepatocellular carcinoma cells driving necroptosis of microvascular endothelial cells through a syndecan-1 / TNF-α axis, which in turn raised trans-endothelial migration. Added to that, heparanase carried in tumor-derived vesicles spreads activity through the microenvironment. These are the reasons heparanase appears as a candidate serum or urine biomarker of tumor burden, and why HPSE genetics attract attention: the rs4693608 variant, sitting in an intronic enhancer, alters HPSE expression and has been linked in research to cancer prognosis, graft-versus-host disease risk, and other inflammatory outcomes.

Figure 2. Major contributions of heparanase-1 in cancer. (Source: Lebsir N, et al. 2023)

Heparanase in Kidney Disease and Inflammation

The same enzyme that helps a tumor spread also helps the kidney leak. Heparan sulfate is a major component of the glomerular endothelial glycocalyx — the charge barrier that keeps albumin in the blood — so when heparanase trims it, albumin escapes. In diabetic nephropathy, a 2022 study found heparanase over-expression in glomerular endothelial cells driving endothelial-to-mesenchymal transition through ERK signaling, with heparanase levels correlating directly with proteinuria and mesangial expansion; mice lacking the enzyme were protected from albuminuria in experimental diabetes. That places heparanase on the short list of targets for proteinuric kidney disease. Beyond the kidney, heparanase contributes to rheumatoid arthritis and other chronic inflammatory conditions, where matrix degradation and growth-factor release feed tissue damage. Notably, some of these effects are independent of enzymatic cleavage: heparanase can sit in the nucleus as part of a chromatin complex that shapes histone methylation, and at the cell surface it can act as a co-receptor that potentiates EGFR and integrin signaling and switches on kinase pathways such as p38, ERK, and Akt.

How Heparanase Is Measured

Two fundamentally different readouts exist. An activity assay uses a heparan sulfate substrate — typically radiolabeled or fluorophore-tagged — and reports catalytic function, which is what matters biologically. A protein ELISA reports heparanase mass but cannot distinguish the active heterodimer from inactive precursor or cleavage fragments, so a high ELISA value does not prove high activity. Sample choice matters: serum, plasma, and urine have all been used, but heparin and contaminating sulfated glycosaminoglycans can interfere with activity formats, and free heparan sulfate in a sample competes for the substrate. A 2024 methodological review catalogued the current reagent toolbox for interrogating heparanase activity and stressed that comparing studies requires agreeing on substrate, pH, and how "active enzyme" is defined. For most biomarker work the pragmatic approach is to pair a mass assay with an activity assay rather than rely on either alone.

Outlook

The therapeutic logic is straightforward — block heparanase, blunt metastasis and matrix breakdown — but execution has been hard. Several inhibitor classes have been explored, including heparan sulfate mimetics that compete for the substrate-binding site and mechanism-based compounds that bind the active site irreversibly; a 2022 study reported nanomolar, heparanase-specific irreversible inhibitors that reduced metastasis in animal models. None is clinically approved yet, which keeps the field active. On the diagnostic side, the move is toward combining HPSE mass, activity, and genetic variants into a single panel, and toward activity-normalized reporting so that a "heparanase level" finally means something consistent across labs.